Unibest

Pharmaceutical intermediates

Afatinib Intermediates

1 pharmaceutical intermediate for Afatinib. Indication: Carcinoma, Non-Small-Cell Lung.

Submit a ProjectAll intermediates

About Afatinib

Originator
Boehringer Ingelheim
Indication
Carcinoma, Non-Small-Cell Lung
Approved Date
07/12/2013
DS/DP
01/13/2026

Available intermediates

1 intermediate currently listed for Afatinib. Request specifications, documentation or a quotation for any item below.

Afatinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-aMine162012-67-1//

Other programs under A

AbemaciclibAbrocitinibAcalabrutinibAdagrasibAfoxolanerAlectinib HydrochlorideAlfacalcidolAlogliptin/ Trelagliptin

Building toward Afatinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →